News
Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease
Published on: September 21, 2022 View the full News here; Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights.
Engagement in New Consortium in Huntington’s disease
Published on: 10th May 2022 View the full News here; Engagement in new consortium in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights. IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis.
IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology
Published on Proactive: 14th Feb, 2022 The new platform has been developed and validated in collaboration with academic and pharma partners, the company said. IXICO said its next-generation brain imaging technology that is more sensitive, accurate and flexible than the current platform will be available for clinical trials from next month (March).
Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances
Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months.…
"As clinical trials become more complex, we're seeing the [use of] medical imaging increasing" says Giulio Cerroni in S&P Global Market Intelligence interviewNew Blog Post
IXICO has been featured in S&P Global Market Intelligence's recently published article focused on use of AI technology in drug development. The article entitled 'Big Pharma recruits NASA scientist, sets up command centers in AI push' by Etain Lavelle was originally published here.
AMYPAD's interview with Katherine Gray, IXICO's associate director of technologyNew Blog Post
IXICO's Associate Director of Technology, Katherine Gray was featured in AMYPAD's recent newsletter to highlight the work she and others within IXICO's tech & data management teams are doing to support AMYPAD projects, using our TrialTracker platform to improve the quality of imaging data.
BGF investment fund's Paul Stevens: IXICO has “market leading position" & “impressive commercial traction”
The comments were made during the following Q&A session with Paul Stevens from BGF’s investment fund, who focuses on identifying opportunities among AIM-listed companies: 1. Can you provide some background on BGF and the sectors/types of companies you invest in?BGF was set up in 2011 to help support small growing companies in the UK.
Investors chronicle: 'IXICO upgrades guidance again'
Published on investors chronicle: 15th October Author: Simon Thompson The world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease.
1-8 of 9 results